Buy cheap Arava

Arava (Leflunomide) is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. The chemical name for Arava (Leflunomide) is N-(4'-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide.

Arava is an immunomodulatory drug inhibiting dihydroorotate dehydrogenase (an enzyme involved in de novo pyrimidine synthesis) (abbreviation DHODH). Genuine antiproliferative activity has been proven. Additionally, several experimental models (both in vivo and in vitro) have demonstrated an anti-inflammatory effect. This double action is supposed to slow progression of the disease and to cause remission/relief of symptoms of rheumatoid arthritis and psoriatic arthritis such as joint tenderness and decreased joint and general mobility in human patients.

Relative to an oral solution, Arava tablets are 80% bioavailable. Co-administration of Arava (Leflunomide) tablets with a high fat meal did not have a significant impact on M1 (the main metabolite, see below) plasma levels. Following oral administration, Arava (Leflunomide) is metabolized to an active metabolite A77 1726 (internal reference of Aventis - hereafter referred to as M1) which is responsible for essentially all of the drug's activity in vivo. Studies of the pharmacokinetics of Arava (Leflunomide) have primarily examined the plasma concentrations of this active metabolite M1. Plasma levels of unchanged Arava (Leflunomide) are occasionally detected, but at very low levels. Some minor metabolites have been noticed to occur in human plasma, which do not account for the beneficial drug effects. M1 is metabolized in the liver at cytosolic and microsomal sites and further excreted as well renally and billary.

Absorption and Need for Loading Dose: After oral administration, peak plasma levels of the active metabolite, M1, occurred between 6 - 12 hours after dosing. Due to the very long half-life of M1 (approx. 2 weeks), a loading dose of 100 mg for 3 days was used in clinical studies to reach steady-state levels of M1 quickly. Without a loading dose, it is estimated that steady-state plasma concentrations would require nearly two months of dosing to be reached. The resulting plasma levels following both loading doses and continued clinical dosing indicate that M1 plasma levels are dose proportional. M1 can be found as late as 2 years after termination of therapy in human plasma in sufficient levels to cause severe harm to pregnant women or to cause significant interactions. If quick removal of M1 from the body is warranted, an eleven day scheme with cholestyramine or the use of activated charcoal is indicated and will soon decrease M1 plasma levels below the critical limit of 0.02mg/l. Limited experience shows that M1 is not dialysable.

What is the shelf life of the pills?

• The expiry date is mentioned on each blister. It is different for different batches. The shelf life is 2 years from the date of manufacture and would differ from batch to batch depending on when they were manufactured.